Systemic anti-CD25 monoclonal antibody administration safely enhances immunity in murine glioma without eliminating regulatory T cells.
about
Biomarkers for glioma immunotherapy: the next generationImmunotherapy advances for glioblastomaAn update on vaccine therapy and other immunotherapeutic approaches for glioblastomaMonitoring of regulatory T cell frequencies and expression of CTLA-4 on T cells, before and after DC vaccination, can predict survival in GBM patientsA pilot study of IL-2Rα blockade during lymphopenia depletes regulatory T-cells and correlates with enhanced immunity in patients with glioblastomaInflammation and Gliomagenesis: Bi-Directional Communication at Early and Late Stages of Tumor Progression.IL-10 from CD4CD25Foxp3CD127 adaptive regulatory T cells modulates parasite clearance and pathology during malaria infection.Treg depletion inhibits efficacy of cancer immunotherapy: implications for clinical trials.Effect of attenuation of Treg during BCG immunization on anti-mycobacterial Th1 responses and protection against Mycobacterium tuberculosis.A Combination of Systemic and Intracranial Anti-CD25 Immunotherapy Elicits a Long-Time Survival in Murine Model of GliomaDurable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors.Partial regulatory T cell depletion prior to schistosomiasis vaccination does not enhance the protectionImmunotherapy coming of age: what will it take to make it standard of care for glioblastoma?Manipulation of Innate and Adaptive Immunity through Cancer Vaccines.Immunotherapy of brain cancers: the past, the present, and future directions.Anti-inflammatory treatments during the chronic phase of spinal cord injury improve locomotor function in adult mice.Monoclonal antibody blockade of IL-2 receptor α during lymphopenia selectively depletes regulatory T cells in mice and humans.Glioma-derived T cell immunoglobulin- and mucin domain-containing molecule-4 (TIM4) contributes to tumor toleranceGenetic analysis of intracranial tumors in a murine model of glioma demonstrate a shift in gene expression in response to host immunity.PI3K pathway inhibitors: potential prospects as adjuncts to vaccine immunotherapy for glioblastoma.Immunotherapy of malignant brain tumors.IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity.Incomplete depletion and rapid regeneration of Foxp3+ regulatory T cells following anti-CD25 treatment in malaria-infected mice.Incomplete tumour control following DNA vaccination against rat gliomas expressing a model antigen.Serum elevation of B lymphocyte stimulator does not increase regulatory B cells in glioblastoma patients undergoing immunotherapy.Increased proportion of FoxP3+ regulatory T cells in tumor infiltrating lymphocytes is associated with tumor recurrence and reduced survival in patients with glioblastoma.Role of monoclonal antibodies in tumor-specific immunity.Regulatory T cells move in when gliomas say "I Do".Impact of anti-CD25 monoclonal antibody on dendritic cell-tumor fusion vaccine efficacy in a murine melanoma model.A novel inhibitor of signal transducers and activators of transcription 3 activation is efficacious against established central nervous system melanoma and inhibits regulatory T cellsFlt3L and TK gene therapy eradicate multifocal glioma in a syngeneic glioblastoma model.Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: case studyTargeting epidermal growth factor receptor variant III: a novel strategy for the therapy of malignant glioma.Prioritization schema for immunotherapy clinical trials in glioblastoma.A novel phosphorylated STAT3 inhibitor enhances T cell cytotoxicity against melanoma through inhibition of regulatory T cells.Combating immunosuppression in gliomaTumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma.Regulatory T cells control strain specific resistance to Experimental Autoimmune ProstatitisDC vaccination with anti-CD25 treatment leads to long-term immunity against experimental glioma.Immune-checkpoint blockade and active immunotherapy for glioma.
P2860
Q26825496-AA505867-CF4C-4C87-8F9B-D35D14B9D416Q26866513-99C9B42D-B3DB-4AC1-B5B4-5BABF46EB9DBQ27024830-E7723591-D711-4D9B-BA3A-E624DA632D73Q28730798-959A69A6-333F-4D29-A508-1A694D7E6683Q28731711-D143853C-5DDF-4EE7-A3FE-921403B6D242Q30414501-EAAFFC6B-F1E7-4E22-9309-A5FC24D65FD1Q33327498-EB3A9A13-10E9-4668-873D-51917F0A1BF2Q33330270-06228E71-BE44-44F0-9D00-56BBC1BC467CQ33355965-21BE0759-4A23-4C89-B4FB-6AFD7445C772Q33743905-E7766D09-AA02-4D2D-AD41-23E4C60DDCC0Q34276759-F5963F0D-2185-4D10-8A10-EF33DA9972A2Q34339707-FD46FF7A-AD4A-4A9C-893F-80DC46C21E12Q34480557-2C0ECC47-FF46-407C-B659-1AA86D76F067Q34552791-339FDB71-9C9C-4E68-BDA0-9CC9F22C737CQ34701587-625A6F83-1BCD-4FD0-9FD6-45938002BF32Q35212541-FBCB4C2B-01DD-4C65-8D14-39004C4638DFQ35220386-FB2BB71D-B3BD-428E-ACB9-B0B6B2FAFA2FQ35378998-5E892B69-22A7-4769-9C23-02D3E5CC06DFQ35783111-716C917D-97C7-43B2-876C-A0CFAE3710EBQ36086507-BC7383F2-1CBD-4F34-B78D-A402C389A647Q36162929-C1F00939-1B3B-411D-89D7-C5EA9EBBC0F7Q36384826-7A7D5712-FB5A-4552-88D9-00E04F8D7529Q36449594-D5B340B9-85B3-47F3-A3FB-5B1CCE56DA77Q36503464-417AE96E-02ED-455A-BE1B-E0BA133A566AQ36558234-7401DF57-EC9A-4E06-9FEA-B039ABEECCCFQ36639475-AF5ACB65-14E8-4448-A46B-85099F82BFEDQ36739762-F1BBAC0D-1D05-43AC-9171-C7760D29FDF9Q36872066-F9E9CBA6-04A3-4A5A-A559-7EB504274A31Q36952541-9BBF5A11-F7ED-42BC-8A16-677191BC3B4AQ36973832-46034548-03C1-43ED-820E-CDCF66F18BBEQ37010979-DA2A5C4E-7903-4AF1-A55A-E4356379EFBEQ37011021-CCA7F148-3A02-432C-A57F-2E767C3B2151Q37030810-642BA4EA-6B99-44A8-B803-029E2D7BF213Q37078999-C812AA33-9726-47C5-A117-4B496EF3B5D8Q37172697-F528DEDC-6193-4725-92C7-D84294506CE4Q37179415-CB188E83-E5BA-4807-B325-77FE969B321DQ37186248-C9FC758A-240F-4637-83CD-BA8226655C83Q37254342-FA1EE95D-E28C-4992-AF15-38E538F6CB7DQ37395354-A3728700-A123-428D-A112-14E5505C60DEQ37420586-EA6D452E-8187-49E1-A2DD-527FF7B445CA
P2860
Systemic anti-CD25 monoclonal antibody administration safely enhances immunity in murine glioma without eliminating regulatory T cells.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Systemic anti-CD25 monoclonal ...... liminating regulatory T cells.
@en
type
label
Systemic anti-CD25 monoclonal ...... liminating regulatory T cells.
@en
prefLabel
Systemic anti-CD25 monoclonal ...... liminating regulatory T cells.
@en
P2093
P1476
Systemic anti-CD25 monoclonal ...... liminating regulatory T cells.
@en
P2093
Alison E Sweeney
Christopher A Learn
Duane A Mitchell
Eli Gilboa
John H Sampson
Peter E Fecci
Peter M Grossi
Smita K Nair
Thomas J Cummings
P304
P356
10.1158/1078-0432.CCR-06-0053
P407
P433
P577
2006-07-01T00:00:00Z